A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Nov 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 17 Nov 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History